Safety and tolerability of escalating single doses of the hepatitis B virus RNA interference drug ARC- 521 in a healthy volunteer population

Trial Profile

Safety and tolerability of escalating single doses of the hepatitis B virus RNA interference drug ARC- 521 in a healthy volunteer population

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Jul 2017

At a glance

  • Drugs ARC 521 (Primary)
  • Indications Unspecified
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jul 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top